These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3315956)

  • 1. ras p21 expression in the progression of breast cancer.
    Fromowitz FB; Viola MV; Chao S; Oravez S; Mishriki Y; Finkel G; Grimson R; Lundy J
    Hum Pathol; 1987 Dec; 18(12):1268-75. PubMed ID: 3315956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras oncogene and the acquisition of metastasizing properties by rectal adenocarcinoma.
    Michelassi F; Erroi F; Roncella M; Block GE
    Dis Colon Rectum; 1989 Aug; 32(8):665-8. PubMed ID: 2666052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated ras oncogene expression correlates with lymph node metastases in breast cancer patients.
    Lundy J; Grimson R; Mishriki Y; Chao S; Oravez S; Fromowitz F; Viola MV
    J Clin Oncol; 1986 Sep; 4(9):1321-5. PubMed ID: 3528401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease.
    Candlish W; Kerr IB; Simpson HW
    J Pathol; 1986 Nov; 150(3):163-7. PubMed ID: 3027290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas.
    Czerniak B; Chen R; Tuziak T; Markiewski M; Kram A; Gorczyca W; Deitch D; Herz F; Koss LG
    Cancer; 1989 May; 63(10):2008-13. PubMed ID: 2467732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers.
    Yoshida K; Hamatani K; Koide H; Ikeda H; Nakamura N; Akiyama M; Tsuchiyama H; Nakayama E; Shiku H
    Cancer Res; 1988 Oct; 48(19):5503-9. PubMed ID: 3046740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ras p21 overexpression is a late event in prostate-cancer.
    Hamdy S; Aprikian A; Begin L; Fair W; Bazinet M
    Int J Oncol; 1994 Mar; 4(3):627-31. PubMed ID: 21566969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
    Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
    Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of HER-2/neu expression over time and at multiple metastatic sites.
    Niehans GA; Singleton TP; Dykoski D; Kiang DT
    J Natl Cancer Inst; 1993 Aug; 85(15):1230-5. PubMed ID: 8101229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining of colorectal tissues with monoclonal antibodies to ras oncogene p21 product and carbohydrate determinant antigen 19-9.
    Allen DC; Foster H; Orchin JC; Biggart JD
    J Clin Pathol; 1987 Feb; 40(2):157-62. PubMed ID: 3546394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer.
    Miyahara M; Saito T; Kaketani K; Sato K; Kuwahara A; Shimoda K; Kobayashi M
    Dis Colon Rectum; 1991 Dec; 34(12):1097-102. PubMed ID: 1959459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of ras oncogene p21 protein in esophageal squamous cell carcinoma.
    Ruol A; Stephens JK; Michelassi F; Segalin A; Chiarelli S; Peracchia A; Skinner DB; Little AG
    J Surg Oncol; 1990 Jul; 44(3):142-5. PubMed ID: 2196399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of ras p21 oncogene product on human bladder tumors.
    Moriyama N; Umeda T; Akaza H; Taniguchi J; Kitamura T; Murakami T; Kawabe K; Aso Y
    Urol Int; 1989; 44(5):260-3. PubMed ID: 2678672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
    Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
    Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.
    Hand PH; Thor A; Wunderlich D; Muraro R; Caruso A; Schlom J
    Proc Natl Acad Sci U S A; 1984 Aug; 81(16):5227-31. PubMed ID: 6382261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer.
    Hainsworth PJ; Henderson MA; Stillwell RG; Bennett RC
    Eur J Surg Oncol; 1991 Feb; 17(1):9-15. PubMed ID: 1671658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class I antigen expression is inversely related with tumor malignancy and ras oncogene product (p21ras) levels in human breast tumors.
    Solana R; Romero J; Alonso C; Peña J
    Invasion Metastasis; 1992; 12(3-4):210-7. PubMed ID: 1294532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of ras gene expression in stomach cancer by anti-ras p21 monoclonal antibodies.
    Yoshida K; Hamatani K; Koide H; Abe Y; Ikeda H; Tsuchiyama H; Nakayama E; Shiku H
    Cancer Detect Prev; 1988; 12(1-6):369-76. PubMed ID: 3052835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathology.
    Saccani Jotti G; Fontanesi M; Bombardieri E; Gabrielli M; Veronesi P; Bianchi M; Becchi G; Bogni A; Tardini A
    Int J Biol Markers; 1992; 7(1):35-42. PubMed ID: 1349907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.